Loading...
•
Mar 31, 2024
Amicus Therapeutics Q1 2024 Earnings Report
Amicus Therapeutics reported a strong start to the year with excellent commercial performance and significant total revenue growth.
Key Takeaways
Amicus Therapeutics announced its Q1 2024 financial results, highlighting a 28% year-over-year increase in total revenue, reaching $110.4 million. The company is raising its full-year 2024 Galafold guidance and is pleased with the strong commercial launch of Pombiliti and Opfolda. Amicus reiterates its full-year non-GAAP profitability projection for 2024.
Total revenue for Q1 2024 reached $110.4 million, a 28% increase year-over-year.
The company is guiding to full-year 2024 total revenue growth of 25%-30% at CER.
Full-year 2024 Galafold guidance was raised due to continued strong demand.
Pombiliti and Opfolda experienced a strong commercial launch with an increasing rate of commercial patient starts.
Revenue by Segment
Forward Guidance
Amicus is focused on key strategic priorities in 2024, expecting significant total revenue growth and full year non-GAAP profitability.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...